



## Johnson & Johnson Reports 2009 Fourth-Quarter and Full-Year Results:

**--2009 Fourth-Quarter Sales of \$16.6 Billion increased 9.0%; EPS was \$0.79 --2009 Full-Year Sales of \$61.9 Billion decreased 2.9%; Full-Year EPS was \$4.40 --Excluding Special Items, 2009 Fourth-Quarter EPS was \$1.02, an increase of 8.5% --And 2009 Full-Year EPS was \$4.63, an increase of 1.8%\***

NEW BRUNSWICK, N.J., Jan 26, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson today announced sales of \$16.6 billion for the fourth quarter of 2009, an increase of 9.0% as compared to the fourth quarter of 2008. Operational growth was 4.5% and currency contributed 4.5%. Domestic sales were up 2.6%, while international sales increased 15.6%, reflecting operational growth of 6.4% and a positive currency impact of 9.2%. Worldwide sales for the full-year 2009 were \$61.9 billion, a decrease of 2.9% over 2008. Operational results declined 0.3% and the negative impact of currency was 2.6%. Domestic sales declined 4.4%, while international sales declined 1.4%, reflecting operational growth of 3.9% and a negative currency impact of 5.3%.

Net earnings and diluted earnings per share for the fourth quarter of 2009 were \$2.2 billion and \$0.79 respectively. Fourth quarter 2009 net earnings included an after-tax restructuring charge of \$852 million and an after-tax gain of \$212 million representing the net impact of litigation matters. Fourth quarter 2008 net earnings included special items related to in-process research and development charges of \$141 million with no tax benefit and an after-tax gain of \$229 million representing the net impact of litigation matters. Excluding these special items, net earnings for the current quarter were \$2.8 billion and diluted earnings per share were \$1.02, representing increases of 8.4% and 8.5%, respectively, as compared to the same period in 2008.\*

Net earnings and diluted earnings per share for the full-year 2009 were \$12.3 billion and \$4.40. Full-year 2009 net earnings included an after-tax restructuring charge of \$852 million and an after-tax gain of \$212 million representing the net impact of litigation matters. Full-year 2008 net earnings included special items related to in-process research and development charges of \$181 million with no tax benefit and an after-tax gain of \$229 million representing the net impact of litigation matters. Excluding these special items, net earnings for the full-year 2009 were \$12.9 billion. Diluted earnings per share for the full-year 2009 were \$4.63, representing an increase of 1.8%, as compared with the full-year in 2008.\*

The Company announced earnings guidance for full-year 2010 of \$4.85 to \$4.95 per share, which excludes the impact of special items.

"In a year of tremendous challenge, we maintained our long-term focus while delivering solid results -- a great tribute to the employees of Johnson & Johnson," said William C. Weldon, Chairman and Chief Executive Officer. "We made important investments in acquisitions, strategic partnerships and launches of recently-approved innovative products while preserving our financial flexibility to continue to invest in innovation. This positions us well for continued leadership and growth in global health care as we enter 2010."

Worldwide Consumer sales of \$15.8 billion for the full-year 2009 represented a decrease of 1.6% over the prior year with operational growth of 2.0% and a negative currency impact of 3.6%. Domestic sales decreased 1.4%; international sales decreased 1.7%, which reflected operational growth of 4.7% and a negative currency impact of 6.4%.

Primary contributors to operational growth included NEUTROGENA<sup>®</sup>, AVEENO<sup>®</sup> and the Dabao skin care products; international sales of LISTERINE<sup>®</sup> antiseptic mouthrinse; SPLENDA<sup>®</sup> No Calorie Sweetener; and sales from the acquisition of Vania Expansion SNC. Sales growth was negatively impacted due to the initial build of inventory by the trade related to the 2008 launch of Zyrtec.

Worldwide Pharmaceutical sales of \$22.5 billion for the full-year 2009 represented a decrease of 8.3% versus the prior year with an operational decline of 6.1% and a negative impact from currency of 2.2%. Domestic sales decreased 12.1%; international sales decreased 2.6%, which reflected an operational increase of 3.0% and a negative currency impact of 5.6%.

Products with strong operational growth included REMICADE<sup>®</sup> (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA<sup>®</sup> (darunavir), a treatment for HIV; VELCADE<sup>®</sup> (bortezomib), a treatment for multiple myeloma; and RISPERDAL<sup>®</sup> CONSTA<sup>®</sup> (risperidone) Long-Acting Treatment, an antipsychotic medication.

Sales results of TOPAMAX<sup>®</sup> (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL<sup>®</sup> (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the Company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for tapentadol extended release tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older. In addition, the Company submitted a Marketing Authorization Application to the European Medicines Agency for paliperidone palmitate, a once-monthly atypical antipsychotic intramuscular injection for the treatment of adults with schizophrenia.

Worldwide Medical Devices and Diagnostics sales of \$23.6 billion for the full-year 2009 represented an increase of 1.9% versus the prior year with an operational increase of 4.2% and a negative impact from currency of 2.3%. Domestic sales increased 4.5%; international sales decreased 0.2%, which reflected an operational increase of 4.0% and a negative currency impact of 4.2%.

Primary contributors to operational growth included Ethicon's surgical care and aesthetics products; DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses; Ethicon Endo-Surgery's minimally invasive products; and Ortho-Clinical Diagnostics' professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.

During the quarter, the Company entered into a definitive agreement to acquire Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat. On January 20, 2010, the acquisition of Acclarent was completed. Also in the quarter, the Company completed the acquisitions of Finsbury Orthopaedics Limited, a privately held UK-based manufacturer and global distributor of orthopaedic implants, and Gloster Europe, a privately held developer of innovative disinfection processes and technologies to prevent healthcare-acquired infections.

The Company also announced that it had received FDA clearance for marketing the CARTO® 3 System, the most advanced three-dimensional imaging technology for use by electrophysiologists in treating cardiac arrhythmias, commonly referred to as irregular heart rhythms.

#### About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 115,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

\* Net earnings and diluted earnings per share excluding special items, such as after-tax restructuring charges, the net impact of litigation gains and in-process research and development charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at [www.jnj.com](http://www.jnj.com).

#### NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at [www.investor.jnj.com](http://www.investor.jnj.com). A replay and podcast will be available approximately two hours after the live webcast by visiting [www.investor.jnj.com](http://www.investor.jnj.com).

Copies of the financial schedules accompanying this press release are available at [www.investor.jnj.com/historical-sales.cfm](http://www.investor.jnj.com/historical-sales.cfm). The schedules include supplementary sales data, a condensed consolidated statement of earnings, sales of key products/franchises and a pharmaceutical pipeline of selected compounds in late stage development. Additional information on Johnson & Johnson can be found on the Company's website at [www.jnj.com](http://www.jnj.com).

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at [www.sec.gov](http://www.sec.gov), [www.jnj.com](http://www.jnj.com) or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries  
Supplementary Sales Data

(Unaudited;  
Dollars in  
Millions)

FOURTH QUARTER\*

			Percent Change		
	2009	2008	Total	Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$1,712	1,655	3.4%	3.4	-
International	2,537	2,200	15.3	6.5	8.8
-----	4,249	3,855	10.2	5.2	5.0
-----					
Pharmaceutical					
U.S.	3,338	3,430	(2.7)	(2.7)	-
International	2,655	2,255	17.7	8.0	9.7
-----	5,993	5,685	5.4	1.6	3.8
-----					
Med Devices & Diagnostics					
U.S.	2,817	2,582	9.1	9.1	-
International	3,492	3,060	14.1	4.9	9.2
-----	6,309	5,642	11.8	6.8	5.0
-----					
U.S.	7,867	7,667	2.6	2.6	-
International	8,684	7,515	15.6	6.4	9.2
-----					
Worldwide	\$16,551	15,182	9.0%	4.5	4.5
-----					

(Unaudited;  
Dollars in  
Millions)

TWELVE MONTHS\*\*

			Percent Change		
	2009	2008	Total	Operations	Currency
Sales to customers by segment of business					

Consumer

U.S.	\$6,837	6,937	(1.4)%	(1.4)	-
International	8,966	9,117	(1.7)	4.7	(6.4)
-----	-----	-----	----	---	----
	15,803	16,054	(1.6)	2.0	(3.6)
	-----	-----	----	---	----

Pharmaceutical

U.S.	13,041	14,831	(12.1)	(12.1)	-
International	9,479	9,736	(2.6)	3.0	(5.6)
-----	-----	-----	----	---	----
	22,520	24,567	(8.3)	(6.1)	(2.2)
	-----	-----	----	---	----

Med Devices &  
Diagnostics

U.S.	11,011	10,541	4.5	4.5	-
International	12,563	12,585	(0.2)	4.0	(4.2)
-----	-----	-----	----	---	----
	23,574	23,126	1.9	4.2	(2.3)
	-----	-----	----	---	----

U.S.	30,889	32,309	(4.4)	(4.4)	-
International	31,008	31,438	(1.4)	3.9	(5.3)
-----	-----	-----	----	---	----

Worldwide	\$61,897	63,747	(2.9)%	(0.3)	(2.6)
-----	-----	-----	----	---	----

\*Fourth Quarter 2009 includes fourteen weeks and 2008 includes thirteen weeks.

\*\*Twelve Months 2009 includes fifty-three weeks and 2008 includes fifty-two weeks.

Johnson & Johnson and Subsidiaries  
Supplementary Sales Data

(Unaudited;  
Dollars in  
Millions)

FOURTH QUARTER\*

	2009	2008	Percent Change		
			Total	Operations	Currency
-----	----	----	----	-----	-----
Sales to customers by geographic area					
U.S.	\$7,867	7,667	2.6%	2.6	-
-----	-----	-----	----	---	----
Europe	4,412	3,851	14.6	5.1	9.5
Western Hemisphere excluding U.S.	1,541	1,187	29.8	19.0	10.8
Asia-Pacific,					

Africa	2,731	2,477	10.3	2.3	8.0
-----	-----	-----	-----	---	---
International	8,684	7,515	15.6	6.4	9.2
-----	-----	-----	-----	---	---
Worldwide	\$16,551	15,182	9.0%	4.5	4.5
-----	-----	-----	---	---	---

(Unaudited;  
Dollars in  
Millions)

TWELVE MONTHS\*\*

	2009	2008	Total	Percent Change	
				Operations	Currency
-----	----	----	-----	-----	-----
Sales to customers by geographic area					
U.S.	\$30,889	32,309	(4.4)%	(4.4)	-
-----	-----	-----	-----	-----	---
Europe	15,934	16,782	(5.1)	2.1	(7.2)
Western Hemisphere excluding U.S.	5,156	5,173	(0.3)	8.8	(9.1)
Asia-Pacific, Africa	9,918	9,483	4.6	4.4	0.2
-----	-----	-----	---	---	---
International	31,008	31,438	(1.4)	3.9	(5.3)
-----	-----	-----	-----	---	-----
Worldwide	\$61,897	63,747	(2.9)%	(0.3)	(2.6)
-----	-----	-----	-----	-----	-----

\*Fourth Quarter 2009 includes fourteen weeks and 2008 includes thirteen weeks.

\*\*Twelve Months 2009 includes fifty-three weeks and 2008 includes fifty-two weeks.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in  
Millions Except  
Per Share  
Figures)

FOURTH QUARTER

2009

2008

	Amount	Percent to Sales	Amount	Percent to Sales	Percent Increase (Decrease)		
Sales to customers	\$16,551	100.0	\$15,182	100.0	9.0		
Cost of products sold	5,312	32.1	4,372	28.8	21.5		
Selling, marketing and administrative expenses	5,629	34.0	5,665	37.3	(0.6)		
Research expense	2,213	13.4	2,108	13.9	5.0		
In-process research & development (IPR&D)	-	-	141	0.9			
Interest (income) expense, net	81	0.5	17	0.1			
Other (income) expense, net	(361)	(2.2)	(638)	(4.2)			
Restructuring expense	1,073	6.5	-	-			
Earnings before provision for taxes on income	2,604	15.7	3,517	23.2	(26.0)		
Provision for taxes on income	398	2.4	803	5.3	(50.4)		
Net earnings	\$2,206	13.3	\$2,714	17.9	(18.7)		
Net earnings per share (Diluted)	\$0.79		\$0.97		(18.6)		
Average shares outstanding (Diluted)	2,796.5		2,801.6				
Effective tax rate	15.3%		22.8%				
Adjusted earnings before provision for taxes and net earnings							
Earnings before provision for taxes on income	\$3,404	(1)	20.6	\$3,279	(2)	21.6	3.8
Net earnings	\$2,846	(1)	17.2	\$2,626	(2)	17.3	8.4
Net earnings per share (Diluted)	\$1.02	(1)		\$0.94	(2)		8.5
Effective tax rate	16.4%			19.9%			

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of \$1,186 million (\$1,073 million restructuring expense and \$113 million related to restructuring included in cost of products sold), \$852 million and \$0.31 per share, respectively, and the exclusion of income from net litigation of \$386 million, \$212 million and \$0.08 per share, respectively.

(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of \$141 million with no tax benefit and \$0.05 per share, respectively, and the exclusion of income from net litigation of \$379 million, \$229 million and \$0.08 per share, respectively.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in  
Millions Except  
Per Share  
Figures)

	2009		2008		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$61,897	100.0	\$63,747	100.0	(2.9)
Cost of products sold	18,447	29.8	18,511	29.1	(0.3)
Selling, marketing and administrative expenses	19,801	32.0	21,490	33.7	(7.9)
Research expense	6,986	11.3	7,577	11.9	(7.8)
In-process research & development (IPR&D)	-	-	181	0.3	
Interest (income) expense, net	361	0.6	74	0.1	
Other (income) expense, net	(526)	(0.8)	(1,015)	(1.6)	
Restructuring expense	1,073	1.7	-	-	
Earnings before provision for taxes on income	15,755	25.4	16,929	26.5	(6.9)
Provision for taxes on income	3,489	5.6	3,980	6.2	(12.3)

Net earnings	\$12,266	19.8	\$12,949	20.3	(5.3)
-----	-----	----	-----	----	----
Net earnings per share (Diluted)	\$4.40		\$4.57		(3.7)
Average shares outstanding (Diluted)	2,789.1		2,835.6		
Effective tax rate	22.1%		23.5%		

-----					
Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$16,555 (1)	26.7	\$16,731 (2)	26.2	(1.1)
Net earnings	\$12,906 (1)	20.9	\$12,901 (2)	20.2	-
Net earnings per share (Diluted)	\$4.63 (1)		\$4.55 (2)		1.8
Effective tax rate	22.0%		22.9%		
-----	----		----		

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of \$1,186 million (\$1,073 million restructuring expense and \$113 million related to restructuring included in cost of products sold), \$852 million and \$0.31 per share, respectively, and the exclusion of income from fourth quarter net litigation of \$386 million, \$212 million and \$0.08 per share, respectively.

(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of \$181 million with no tax benefit and \$0.06 per share, respectively, and the exclusion of income from fourth quarter net litigation of \$379 million, \$229 million and \$0.08 per share, respectively.



**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FOURTH QUARTER</b>					<b>TWELVE MONTHS</b>				
	<b>2009</b>	<b>2008</b>	<b>% Change</b>			<b>2009</b>	<b>2008</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b>SKIN CARE</b>										
US	378	343	10.2%	10.2%	-	1,582	1,462	8.2%	8.2%	-
Intl	572	501	14.2%	6.7%	7.5%	1,885	1,919	-1.8%	3.9%	-5.7%
WW	950	844	12.6%	8.1%	4.5%	3,467	3,381	2.5%	5.7%	-3.2%
<b>BABY CARE</b>										
US	106	109	-2.8%	-2.8%	-	414	449	-7.8%	-7.8%	-
Intl	468	414	13.0%	5.0%	8.0%	1,701	1,765	-3.6%	1.7%	-5.3%
WW	574	523	9.8%	3.4%	6.4%	2,115	2,214	-4.5%	-0.2%	-4.3%
<b>ORAL CARE</b>										
US	167	192	-13.0%	-13.0%	-	716	780	-8.2%	-8.2%	-
Intl	241	204	18.1%	9.1%	9.0%	853	844	1.1%	8.6%	-7.5%
WW	408	396	3.0%	-1.7%	4.7%	1,569	1,624	-3.4%	0.5%	-3.9%
<b>OTC/NUTRITIONALS</b>										
US	807	762	5.9%	5.9%	-	2,944	3,061	-3.8%	-3.8%	-
Intl	767	694	10.5%	2.2%	8.3%	2,686	2,833	-5.2%	1.9%	-7.1%
WW	1,574	1,456	8.1%	4.2%	3.9%	5,630	5,894	-4.5%	-1.1%	-3.4%
<b>WOMEN'S HEALTH</b>										
US	135	148	-8.8%	-8.8%	-	578	618	-6.5%	-6.5%	-
Intl	354	288	22.9%	12.4%	10.5%	1,317	1,293	1.9%	8.4%	-6.5%
WW	489	436	12.2%	5.2%	7.0%	1,895	1,911	-0.8%	3.6%	-4.4%
<b>WOUND CARE / OTHER</b>										
US	119	101	17.8%	17.8%	-	603	567	6.3%	6.3%	-
Intl	135	99	36.4%	20.2%	16.2%	524	463	13.2%	19.9%	-6.7%
WW	254	200	27.0%	20.0%	7.0%	1,127	1,030	9.4%	12.2%	-2.8%
<b>TOTAL CONSUMER</b>										
US	1,712	1,655	3.4%	3.4%	-	6,837	6,937	-1.4%	-1.4%	-
Intl	2,537	2,200	15.3%	6.5%	8.8%	8,966	9,117	-1.7%	4.7%	-6.4%
WW	4,249	3,855	10.2%	5.2%	5.0%	15,803	16,054	-1.6%	2.0%	-3.6%

\* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2)</sup></b>										
<b>ACIPHEX/PARIET</b>										
US	158	140	12.9%	12.9%	-	555	539	3.0%	3.0%	-
Intl	154	134	14.9%	2.7%	12.2%	541	619	-12.6%	-6.7%	-5.9%
WW	312	274	13.9%	8.0%	5.9%	1,096	1,158	-5.4%	-2.3%	-3.1%
<b>CONCERTA</b>										
US	279	208	34.1%	34.1%	-	986	830	18.8%	18.8%	-
Intl	102	72	41.7%	31.2%	10.5%	340	417	-18.5%	-11.9%	-6.6%
WW	381	280	36.1%	33.4%	2.7%	1,326	1,247	6.3%	8.5%	-2.2%
<b>DURAGESIC/FENTANYL TRANSDERMAL</b>										
US	53	72	-26.4%	-26.4%	-	216	271	-20.3%	-20.3%	-
Intl	180	200	-10.0%	-19.4%	9.4%	672	765	-12.2%	-8.3%	-3.9%
WW	233	272	-14.3%	-21.2%	6.9%	888	1,036	-14.3%	-11.4%	-2.9%
<b>LEVAQUIN/FLOXIN</b>										
US	433	393	10.2%	10.2%	-	1,478	1,510	-2.1%	-2.1%	-
Intl	19	18	5.6%	1.7%	3.9%	72	81	-11.1%	1.6%	-12.7%
WW	452	411	10.0%	9.8%	0.2%	1,550	1,591	-2.6%	-2.0%	-0.6%
<b>PROCRI/EPREX</b>										
US	308	318	-3.1%	-3.1%	-	1,258	1,332	-5.6%	-5.6%	-
Intl	268	242	10.7%	-0.3%	11.0%	987	1,128	-12.5%	-7.1%	-5.4%
WW	576	560	2.9%	-1.9%	4.8%	2,245	2,460	-8.7%	-6.2%	-2.5%
<b>RAZADYNE/REMINYL</b>										
US	6	11	-45.5%	-45.5%	-	36	134	-73.1%	-73.1%	-
Intl	104	91	14.3%	2.0%	12.3%	379	407	-6.9%	-0.5%	-6.4%
WW	110	102	7.8%	-3.2%	11.0%	415	541	-23.3%	-18.5%	-4.8%
<b>REMICADE</b>										
US	758	672	12.8%	12.8%	-	3,088	2,810	9.9%	9.9%	-
US Exports <sup>(4)</sup>	375	209	79.4%	79.4%	-	1,196	927	29.0%	29.0%	-
Intl	5	5	-	-0.3%	0.3%	20	11	81.8%	78.8%	3.0%
WW	1,138	886	28.4%	28.4%	-	4,304	3,748	14.8%	14.8%	-
<b>RISPERDAL/RISPERIDONE</b>										
US	24	91	-73.6%	-73.6%	-	247	1,287	-80.8%	-80.8%	-
Intl	169	194	-12.9%	-20.9%	8.0%	652	839	-22.3%	-21.2%	-1.1%
WW	193	285	-32.3%	-37.8%	5.5%	899	2,126	-57.7%	-57.3%	-0.4%
<b>RISPERDAL CONSTA</b>										
US	133	117	13.7%	13.7%	-	519	456	13.8%	13.8%	-
Intl	266	202	31.7%	20.6%	11.1%	906	853	6.2%	14.5%	-8.3%
WW	399	319	25.1%	18.1%	7.0%	1,425	1,309	8.9%	14.3%	-5.4%
<b>TOPAMAX</b>										
US	89	576	-84.5%	-84.5%	-	731	2,250	-67.5%	-67.5%	-
Intl	103	104	-1.0%	-11.7%	10.7%	420	481	-12.7%	-5.3%	-7.4%
WW	192	680	-71.8%	-73.4%	1.6%	1,151	2,731	-57.9%	-56.6%	-1.3%
<b>VELCADE</b>										
US	-	-	-	-	-	-	4	-100.0%	-100.0%	-
Intl	281	208	35.1%	26.5%	8.6%	933	783	19.2%	26.7%	-7.5%
WW	281	208	35.1%	26.5%	8.6%	933	787	18.6%	26.0%	-7.4%
<b>OTHER</b>										
US	722	623	15.9%	15.9%	-	2,731	2,481	10.1%	10.1%	-
Intl	1,004	785	27.9%	19.1%	8.8%	3,557	3,352	6.1%	11.4%	-5.3%
WW	1,726	1,408	22.6%	17.7%	4.9%	6,288	5,833	7.8%	10.8%	-3.0%
<b>TOTAL PHARMACEUTICAL</b>										
US	3,338	3,430	-2.7%	-2.7%	-	13,041	14,831	-12.1%	-12.1%	-
Intl	2,655	2,255	17.7%	8.0%	9.7%	9,479	9,736	-2.6%	3.0%	-5.6%
WW	5,993	5,685	5.4%	1.6%	3.8%	22,520	24,567	-8.3%	-6.1%	-2.2%
<b>MAJOR NEW PHARM PRODUCTS <sup>(5)</sup></b>										
<b>PREZISTA</b>										
US	88	50	76.0%	76.0%	-	303	159	90.6%	90.6%	-
Intl	91	43	111.6%	98.7%	12.9%	289	175	65.1%	77.0%	-11.9%
WW	179	93	92.5%	86.5%	6.0%	592	334	77.2%	83.4%	-6.2%
<b>INVEGA</b>										
US	72	70	2.9%	2.9%	-	266	262	1.5%	1.5%	-
Intl	34	25	36.0%	23.8%	12.2%	127	64	98.4%	111.7%	-13.3%
WW	106	95	11.6%	8.4%	3.2%	393	326	20.6%	23.2%	-2.6%

\* See footnotes on page 3

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FOURTH QUARTER</b>					<b>TWELVE MONTHS</b>				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES AND DIAG <sup>(2) (3)</sup></b>										
<b>CORDIS <sup>(6)</sup></b>										
US	240	236	1.7%	1.7%	-	971	1,165	-16.7%	-16.7%	-
Intl	457	448	2.0%	-5.8%	7.8%	1,708	1,823	-6.3%	-4.4%	-1.9%
WW	697	684	1.9%	-3.2%	5.1%	2,679	2,988	-10.3%	-9.1%	-1.2%
<b>DEPUY</b>										
US	828	744	11.3%	11.3%	-	3,096	2,873	7.8%	7.8%	-
Intl	645	546	18.1%	8.3%	9.8%	2,276	2,263	0.6%	7.2%	-6.6%
WW	1,473	1,290	14.2%	10.1%	4.1%	5,372	5,136	4.6%	7.5%	-2.9%
<b>DIABETES CARE</b>										
US	313	275	13.8%	13.8%	-	1,221	1,265	-3.5%	-3.5%	-
Intl	342	304	12.5%	2.9%	9.6%	1,219	1,270	-4.0%	0.8%	-4.8%
WW	655	579	13.1%	8.0%	5.1%	2,440	2,535	-3.7%	-1.3%	-2.4%
<b>ETHICON</b>										
US	458	363	26.2%	26.2%	-	1,754	1,450	21.0%	21.0%	-
Intl	651	555	17.3%	7.5%	9.8%	2,368	2,390	-0.9%	4.5%	-5.4%
WW	1,109	918	20.8%	14.8%	6.0%	4,122	3,840	7.3%	10.7%	-3.4%
<b>ETHICON ENDO-SURGERY</b>										
US	532	515	3.3%	3.3%	-	1,974	1,901	3.8%	3.8%	-
Intl	724	602	20.3%	10.5%	9.8%	2,518	2,385	5.6%	10.6%	-5.0%
WW	1,256	1,117	12.4%	7.0%	5.4%	4,492	4,286	4.8%	7.6%	-2.8%
<b>ORTHO-CLINICAL DIAGNOSTICS</b>										
US	258	248	4.0%	4.0%	-	1,104	997	10.7%	10.7%	-
Intl	243	204	19.1%	10.6%	8.5%	859	844	1.8%	6.3%	-4.5%
WW	501	452	10.8%	6.9%	3.9%	1,963	1,841	6.6%	8.6%	-2.0%
<b>VISION CARE</b>										
US	188	201	-6.5%	-6.5%	-	891	890	0.1%	0.1%	-
Intl	430	401	7.2%	-0.7%	7.9%	1,615	1,610	0.3%	-	0.3%
WW	618	602	2.7%	-2.6%	5.3%	2,506	2,500	0.2%	0.1%	0.1%
<b>TOTAL MEDICAL DEVICES AND DIAG</b>										
US	2,817	2,582	9.1%	9.1%	-	11,011	10,541	4.5%	4.5%	-
Intl	3,492	3,060	14.1%	4.9%	9.2%	12,563	12,585	-0.2%	4.0%	-4.2%
WW	6,309	5,642	11.8%	6.8%	5.0%	23,574	23,126	1.9%	4.2%	-2.3%

<sup>(1)</sup> Operational growth excludes the effect of currency

<sup>(2)</sup> Select areas (unaudited)

<sup>(3)</sup> Prior year amounts have been reclassified to conform with current presentation

<sup>(4)</sup> Reported in U.S. sales

<sup>(5)</sup> Included in Other

<sup>(6)</sup> Includes sales of Drug-Eluting Stents for Q4 2009 of \$56, \$167 and \$223MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q4 2008 of \$70, \$202 and \$272MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for December YTD 2009 of \$245, \$674 and \$919MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for December YTD 2008 of \$503, \$852 and \$1,355MM Domestic, International and Worldwide respectively

SOURCE Johnson & Johnson

Copyright © 2010 PR Newswire. All rights reserved